Pfizer's BRAFTOVI combination regimen receives US FDA approval for treatment of ...
Pfizer announced FDA approval of BRAFTOVI (encorafenib) in combination with cetuximab and mFOLFOX6 for metastatic colorectal cancer (mCRC) with BRAF V600E mutation. The approval is based on the phase 3 BREAKWATER trial, showing significant improvement in response rate and durability of response. The regimen offers new hope for patients with limited treatment options.
Highlighted Terms
Related News
Pfizer's BRAFTOVI combination regimen receives US FDA approval for treatment of ...
Pfizer announced FDA approval of BRAFTOVI (encorafenib) in combination with cetuximab and mFOLFOX6 for metastatic colorectal cancer (mCRC) with BRAF V600E mutation. The approval is based on the phase 3 BREAKWATER trial, showing significant improvement in response rate and durability of response. The regimen offers new hope for patients with limited treatment options.